Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis

被引:6
|
作者
Mori, Kazuma [1 ,8 ]
Akiyama, Yukinori [2 ]
Tanaka, Marenao [1 ]
Sato, Tatsuya [1 ,3 ]
Endo, Keisuke [1 ]
Hosaka, Itaru [4 ]
Hanawa, Nagisa [5 ]
Sakamoto, Naoya [6 ,7 ]
Furuhashi, Masato [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Cardiovasc Renal & Metab Med, S-1,W-16,Chuo Ku, Sapporo 0608543, Japan
[2] Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Japan
[3] Sapporo Med Univ, Sch Med, Dept Cellular Physiol & Signal Transduct, Sapporo, Japan
[4] Sapporo Med Univ, Sch Med, Dept Cardiovasc Surg, Sapporo, Japan
[5] Keijinkai Maruyama Clin, Dept Hlth Checkup & Promot, Sapporo, Japan
[6] Hokkaido Univ, Fac Med, Dept Gastroenterol & Hepatol, Sapporo, Japan
[7] Grad Sch Med, Sapporo, Japan
[8] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Japan
基金
日本学术振兴会;
关键词
clustering; machine learning; metabolic dysfunction-associated fatty liver disease (MAFLD); metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); CLINICAL-PRACTICE GUIDELINES; DELPHI CONSENSUS STATEMENT; ALCOHOL-CONSUMPTION; HEPATITIS-C; INDEX; RISK; INDIVIDUALS; PREVALENCE; MECHANISMS; FACTORIAL;
D O I
10.1111/jgh.16552
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimNew nomenclature of steatotic liver disease (SLD) including metabolic dysfunction-associated SLD (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) has recently been proposed. We investigated clustering analyses to decipher the complex landscape of SLD pathologies including the former nomenclature of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsJapanese individuals who received annual health checkups including abdominal ultrasonography (n = 15 788, men/women: 10 250/5538, mean age: 49 years) were recruited.ResultsThe numbers of individuals with SLD, MASLD, MetALD, ALD, NAFLD, and MAFLD were 5603 (35.5%), 4227 (26.8%), 795 (5.0%), 324 (2.1%), 3982 (25.8%), and 4946 (31.3%), respectively. Clustering analyses using t-distributed stochastic neighbor embedding and K-means to visually represent interconnections in SLDs uncovered five cluster formations. MASLD and NAFLD mainly shared three clusters including (i) low alcohol intake with relatively low-grade obesity; (ii) obesity with dyslipidemia; and (iii) dysfunction of glucose metabolism. Both MetALD and ALD displayed one distinct cluster intertwined with alcohol consumption. MAFLD widely shared all of the five clusters. In machine learning-based analyses using algorithms of random forest and extreme gradient boosting and receiver operating characteristic curve analyses, fatty liver index (FLI), calculated by body mass index, waist circumference, and levels of gamma-glutamyl transferase and triglycerides, was selected as a useful feature for SLDs.ConclusionsThe new nomenclature of SLDs is useful for obtaining a better understanding of liver pathologies and for providing valuable insights into predictive factors and the dynamic interplay of diseases. FLI may be a noninvasive predictive marker for detection of SLDs. 1 image
引用
收藏
页码:1382 / 1393
页数:12
相关论文
共 50 条
  • [11] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    MATURITAS, 2024, 186
  • [12] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [13] In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-associated Steatotic Liver Disease
    Bao, Qinglan
    Zhang, Xiaoxiao
    Chen, Yingsong
    Wang, Tegexibaiyin
    Siqin, Bateer
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2024, (209):
  • [14] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [15] New insights into metabolic dysfunction-associated steatotic liver disease and oxidative balance score
    Peng, Lei
    Li, Lurong
    Liu, Jiahao
    Li, Yuanyuan
    FRONTIERS IN NUTRITION, 2024, 10
  • [16] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [17] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [18] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [19] Mechanobiology in Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity
    Rudolph, Emily L.
    Chin, LiKang
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (07) : 7134 - 7146
  • [20] Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Nendouvhada, Livhuwani P.
    Sibuyi, Nicole R. S.
    Fadaka, Adewale O.
    Meyer, Samantha
    Madiehe, Abram M.
    Meyer, Mervin
    Gabuza, Kwazikwakhe B.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)